

Adapting Prescribing for Symptom Management in Dementia

Dr Catherine Gleeson Consultant – St Catherine's Hospice

Outline



- Context & prevalence
- Why adapt prescribing in dementia?
- The brainy bits
- Prescribing pitfalls & principles
- Anticipated symptoms & adapting prescribing

Context (Alzheimers Society)



- Prevalence of dementia
 - 815 000 in UK (2013)
 - 42 000 under 65y (2013)
- Affects 1 in 6 over 80y
- Two thirds live at home and one third in care home setting, with increasing move to care home setting as disease progresses
- 80% care home residents have dementia or significant cognitive impairment
- Approx 60 000 deaths annually attributed to dementia

Prevalence of dementia (Alz Soc) & symptom clusters (McKeith & Cummings 2005)



Care Compassion Understanding

- Alzheimers 67%
- Vascular 17%
- Mixed 10%

Apathy, depression, delusions, emotional lability. BPSD higher than AD. Increased dyspraxia and falls

Apathy, agitation, anxiety, depression

Behavioural disturbance (delusions &

hallucinations less common)

- Lewy body 4%
- Parkinson's 2%

- Visual hallucinations, delusions, depression, sleep disturbance (REM sleep-behaviour disorder)
- Frontotemporal 2% Apathy, disinhibition

Prevalence of BPSD in advanced dementia



Care Compassion Understanding

BPSD very common ~ 85% have some aspect in advanced dementia

- Agitation / aggression 50%
- Depression 45%
- Withdrawal / lethargy 41%

Dementia associated with other conditions



Care Compassion Understanding

Prevalence of multi-morbidities in >75y (Barnett et al.

- Hypertension 61.9%
- Ischaemic heart disease 31.2%
- Pain 23.6%
- CKD 18.5%
- Depression
- Diabetes & thyroid disease
- COPD
- Hearing & visual impairment

Dementia

- Vascular diseases cardiac arrythmias or failure, multiple CVA
- Parkinson's disease & other neurological conditions (MS, MND, PSP, corticobasal syndrome)

Factors to consider



- Dementia as one of several comorbidities
- Frailty & complex psychosocial context
- Challenges of assessment
- Safe drug administration
- Consent & decision making



Pharmacological Factors to consider



Care Compassion Understanding

Altered organ function affects pharmaco-kinetics

- Reduced liver size 25-35%, reduced hepatic blood flow 40%, affecting first pass metabolism & drug clearance
- GFR affected by ageing & vascular diseases.
 By age 70 ~40% reduction in nephrons
- Weight loss, malnutrition & relative dehydration > reduce vol of distribution > higher serum conc for water sol drugs (Warfarin, Alcohol)
- Obesity increased vol of distribution for lipophilic drugs (Diazepam, Amitryptiline)

Other factors to consider




- Vulnerability to adverse drug effects:
 - Frailty & falls risk
 - Cognitive impairment lowers threshold for sedation & delirium
 - Impaired baroreceptor response > greater risk of postural hypotension
- Polypharmacy (>5 drugs) and adverse drug events
- Guidelines written assuming single disease states & therefore need adjusting for multi-morbidities

Brief neurochemistry next...

To make sense of the drugs








Brief neurochemistry of dementia



Care Compassion Understanding

Acetyl Choline

- Cholinergic neurones relax vascular tone and improve blood flow.
- Higher levels Ach correlate to better MMSE scores
- AD Generalised loss Ach receptors assoc with greater tangles and cognitive impairment
- Reduced cholinergic activity post stoke may cause impaired function in VascD
- DLB Ach loss > AD
- Treatments: Cholinesterase inhibitors increase Ach available at receptors



Brief neurochemistry of dementia



Care Compassion Understanding

Serotonin

- Important in controlling mood, aggression, behaviour and memory
- Reduced levels found in VascD, FTD & AD (although increased 5HT receptors in AD)

Dopamine (D1-5, D2 most important)

- Reduced Dopamine receptors in PDD and DLB, probably explains reduced response to dopaminergic drugs
- Reduced DA may account for dyspraxic gait in Vasc D
- Reduced in FTD > apathy, rigidity & flattened affect

Brief neurochemistry of dementia



Care Compassion Understanding

Glutamate & GABA

- Glutamate main excitatory neurotransmitter
- Important in stimulating processes, learning & memory
- Vasc D -reduced in brain tissue post CVA
- AD- both excess and too little glutamate at different times
- Memantine stimulates Glutamate transmission;
- now recommended for the treatment of core or associated symptoms in people with moderate dementia (NICE guidance 2011)

Prescribing hazards – common scenario



Care Compassion Understanding

Jane, 84, Advanced dementia (mixed) Hypertension, previous MI, AF, Osteoporosis & OA hip

- PS 4, Increased tone with foot drop
- Pressure sore on hip (G2)
- Limited oral intake
- Tendency to constipation
- Poor sleep
- Variable taking meds
- Agitated and calling out repeatedly

Prescribing hazards –which drugs might be problematic?




Care Compassion Understanding

Medication Bisprolol Warfarin Ramipril Statin Baclofen Trazodone Lactulose Tramadol Zopiclone



PRN: Paracetamol, Oramorph, Lorazepam, Haloperidol



Prescribing hazards Polypharmacy



- Substantial evidence that >5 drugs increases risk of ADR, delirium, falls etc and further inc risk in dementia
- Particular drug groups increase risk, many used in management of chronic conditions and palliative care
 - Opioids
 - Benzodiazepines
 - Neuroleptics
 - Anticholinergics
 - Antihistamines

Prescribing hazards Polypharmacy



Care Compassion Understanding

Medications that increase the risk of delirium

Medication class	Odds Ratio
Opioids	2.5
Benzodiazepines	3
Calcium channel blocker	2.4
Antihistamines	1.8
	Davies & Mahanay Br I Clin Dharmanal / 90.4 / 700

Davies & Mahoney, Br J Clin Pharmacol / 80:4 / 799

Prescribing hazards Anticholinergic burden



- Elderly people, particularly those with dementia, sensitive to adverse anticholinergic drug effects
- Often manifests as symptoms of delirium
- Higher risks in dementia due to polypharmacy prescribing for co-morbidities
- Study in Australia community patients 2015:
 - ~60% dementia & 40% non-dementia patients receiving anticholinergic drugs (Mate 2015)
- Importance in considering prescribing for this patient group, particularly for agitation, nausea, pain

the effects of the anticholinergic medicine may be magnified.¹²

Table 1: Commonly used medicines with anticholinergic effects in older veterans^{12, 16}

	Antipsychotics	Antidepressants	Bladder antispasmodics	Antihistamines	Opioids	Inhaled medicines	Other medicines
Higher anticholinergic effects	chlorpromazine clozapine trifluoperazine	amitriptyline clomipramine dothiepin doxepin imipramine nortriptyline	darifenacin* oxybutynin propantheline solifenacin* tolterodine*	cyproheptadine promethazine	tapentadol	aclidinium glycopyrronium ipratropium tiotropium	benztropine homatropine
Lower anticholinergic effects	haloperidol lithium carbonate olanzapine prochlorperazine quetiapine risperidone	citalopram fluoxetine fluvoxamine mirtazapine paroxetine		cetirizine fexofenadine loratadine	codeine fentanyl methadone morphine oxycodone tramadol		alprazolam amantadine baclofen carbamazepine clonazepam colchicine diazepam digoxin disopyramide domperidone entacapone frusemide loperamide metoclopramide ranitidine temazepam theophylline

Note: The list of medicines is based on Duran et al.'s 2013 Systematic review of anticholinergic risk scales in older adults (reviewing 7 studies, one of which was Australian), the Australian Medicines Handbook, Martindale: The Complete Drug Reference and expert opinion.

Note: *these medicines are not available on the PBS/RPBS

Veterans' Medicines Advice and Therapeutics Education Services

Topic 39: Thinking clearly about the anticholinergic burden. Sept 2014.

Drugs on the Anticholinergic Burden (ACB) scale

(A total ACB scale score of three or more is considered clinically relevant)

ACB Score 1 (mild)	ACB Score 2 (moderate)	ACB Score 3 (severe)	
Alimemazine	Amantadine	Amitriptyline	
Alprazolam	Belladonna alkaloids	Amoxapine	
Alverine	Carbamazepine	Atropine	
Atenolol	Cyclobenzaprine	Benztropine	
Beclometasone dipropionate	Cyproheptadine	Chlorpheniramine	
Bupropion hydrochloride	Loxapine	Chlorpromazine	
Captopril	Meperidine	Clemastine	
Chlorthalidone	Methotrimeprazine	Clomipramine	
Cimetidine hydrochloride	Molindone	Clozapine	
Clorazepate	Oxcarbazepine	Darifenacin	
Codeine	Pethidine hydrochloride	Desipramine	
Colchicine	Pimozide	Dicyclomine	
Dextropropoxyphene		Diphenhydramine	
Diazepam		Doxepin	
Digoxin		Flavoxate	
Dipyridamole		Hydroxyzine	
Disopyramide phosphate		Hyoscyamine	
Fentanyl		Imipramine	
Fluvoxamine		Meclizine	
Furosemide		Nortriptyline	
Haloperidol		Orphenadrine	
Hydralazine		Oxybutynin	
Hydrocortisone		Paroxetine	
Isosorbide preparations		Perphenazine	
Loperamide		Procyclidine	
Metoprolol		Promazine	
Morphine		Promethazine	
Nifedipine		Propentheline	
Prednisone/Prednisolone		Pyrilamine	
Quinidine		Scopolamine	
Ranitidine			
Theophylline		Thioridazine (withdrawn) Tolterodine	
Timolol maleate		Trifluoperazine	
Trazodone		Trihexyphenidyl	
Triamterene		Trimipramine	
Warfarin			

nticholinergic burd....pdf

\$1

1 | H

14:30

Prescribing hazards Neuroleptics



- Increased falls, sedation, EPS, CVA and death from all causes (Ballard 2006)
- Up to 60% patient with DLB develop EPS toxicity
- 'Time for Action', (Banerjee 2009) highlighted neuroleptic prescribing in Dementia, questioned benefits; recommended significant reduction & use of non-pharmacological measures for BPSD
- National Dementia and anti-psychotic prescribing audit 2012: 51.8% reduction 2008>2010.
- Inappropriate prescribing still likely need caution and clear rationale for use

Prescribing hazards neuroleptics



- Atypicals some benefit in aggression & psychosis in AD, however evidence of inc risk of CVA (Risperidone) and prolonged QT (Olanzapine)
- Haloperidol some benefit in aggression but EPS limits use
 (SIGN 2006)
- Trazodone insufficient evidence for aggression; may be useful for agitation associated with depression (SIGN 2006)

Principles for prioritising medication



Care Compassion Understanding

7 Steps (Polypharmacy, NHS Scotland)

- 1. Identify aims and objectives of drug therapy.
- 2. Identify essential drug therapy.
- 3. Does the patient take unnecessary drug therapy?
- 4. Are therapeutic objectives being achieved?
- 5. Is the patient at risk of ADRs or suffering actual ADRs?
- 6. Is drug therapy cost-effective?
- 7. Is the patient willing and able to take drug therapy as intended?

STOPP/START criteria

STOPP 65 clinical criteria for potentially inappropriate prescribing in older people, emphasizes potential adverse drug-drug interaction and duplicate drug class prescriptions

<u>BEERS</u> criteria – less helpful as focused on US medications and prescribing (overlaps with STOPP)

Stopping meds – how quickly

(Polypharmacy Guidance 2015)



Care Compassion Understanding

Neuroleptics

- Stop if dementia with cardiac or cerebrovascular risk risk of CVA
- Review if being used for BPSD as limited benefit use non-drug measures
- Continue if co-morbid psychosis, psychotic depression or bipolar disorder seek specialist advice
- Low dose stop without tapering
- Otherwise slow reduction by 25%, review after 1 wk for withdrawal symptoms (N&V, anxiety, agitation, insomnia). If occur consider tapering by 10% steps
- After 4 weeks further 25% reduction etc

Stopping meds – how quickly

(Polypharmacy Guidance 2015)



Care Compassion Understanding

Benzodiazepines

Slow taper to avoid withdrawal – 10% reduction every 1-2 wk Consider switch to Diazepam to manage tapering if:

- Dose/preparation doesn't enable small reductions
- Short-acting BZD (Lorazepam, Alprazolam)

Seek specialist advice if

- History of alcohol or other drug dependence, severe mental health illness
- Previous withdrawal seizures
- Significant hepatic dysfunction

Medicine 'Sick day Rules' (Polypharmacy Guidance 2015)



Care Compassion Understanding

Medicines to stop temporarily if sickness causing dehydration (vomiting, sweating, fever) to avoid acute kidney injury

- ACE inhibitors, ARB
- NSAID
- Diuretics
- Metformin
- Stop while symptoms troublesome (24-72 hrs) and then re-start if appropriate



How often do we do this or advise care homes to do so? Review patients with deteriorating oral intake from dementia

Pain management in dementia



Care Compassion Understanding

- Pain common (~50%), due to co-morbidities, impaired mobility and frailty (Rodger et al 2015)
- Under-diagnosed and under-treated due to staff awareness, assessment skills and patient inability to communicate effectively
- Common cause of aggression & agitation

Consensus

Paracetamol safe

Codeine & compounds – avoid (cognitive s/e, constipation)

NSAIDs - avoid if possible otherwise caution ++

Tramadol – avoid > delirium

Pain management in dementia



Care Compassion Understanding

Opioids

- Start lower doses (eg Morphine 1.25-2.5mg) & titrate with caution
- General prescribing principles same for Morphine & Oxycodone depending on renal function
- Watch for s/e & anticholinergic burden
- Butrans TD advantage due to lower dose & administration
- Fentanyl TD generally too high to start with

Neuropathic pain

Lidocaine TD – generally well tolerated TCA – avoid due to ACB Pregabalin generally prescribed > Gabapentin - caution due to sedation & confusion



Nightmare!!

Nausea

Eliminate potential causes

Consider metabolic, drug related, physical causes

Domperidone

or

Hobson's choice of least worst option & constraints of administration.

Keep lower doses eg metoclopramide 30mg max

BPSD- Agitation and aggression



Care Compassion Understanding

- Look for triggers and causes
- Prioritise non drug measures

Agitation

- + Depression consider SSRI (Escitalopram lower s/e) or Mirtazepine
- + Anxiety non drug measures
- + paranoid features atypical neuroleptic. Review after 6 & 12 weeks. At least 30% can stop without relapse

Aggression

- Weak evidence of benefit with atypicals in AD.
- Risperidone 2mg od is only licensed atypical for BPSD
- Haloperidol NNT 4-5 so caution due to ADR
- Avoid neuroleptics in DLB (less response & greater ADR) seek advice



- Very little evidence for medication being effective in dementia
- Melatonin no evidence

Sleep disorder

- Benzo & 'z' drugs avoid (Case reports of Clonazepam low dose)
- Mirtazepine may help but insufficient evidence
- Best approach is non-drug measures

Seizures



Care Compassion Understanding

Seizures relatively common in advanced dementia Tend to respond well to pharmacological management

Acute management – as usual (Lorazepam or Midazolam)

Preventative

- Some evidence that newer agents better tolerated (eg levotiracetam oral / sc preps)
- Avoid valproate, phenytoin and carbamazepine due to ADR, interactions and pharmaco-kinetics

(Sivaraaman & Vajiala 2015)




- Principles of assessment and tailored prescribing the same
- Caution required due to complex pharmacology and co-morbidities
- Use non-drug measures wherever possible

In essence

In summary

- Don't prescribe unless essential
- Stop more drugs than you start
- Avoid Benzodiazepines, neuroleptics and anticholinergics as far as possible





 Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research and medical education: a cross sectional study. Lancet 2012; 380:37

References

- McLean G, Gunn J, Wyke S, Guthrie B, Watt GC, Blane DN, Mercer SW. The influence of socioeconomic deprivation on multimorbidity at different ages: a crosssectional stufy. Br J Gen Pract 2014; 64: 440-7
- Davies EA, O'Mahoney, MS. Adverse Drug Reactions in special populations the elderly. Br J Clin Pharmacol 2015; 80:4 796-807
- Mate, K et al Impact of multiple low-level anticholinergic medications on anticholinergic load of community-dwelling elderly with and without dementia. <u>Drugs</u> <u>Aging.</u> 2015 Feb;32(2):159-67. doi: 10.1007/s40266-014-0230-0
- Scottish Intercollegiate Guidelines network, Management of people with Dementia, 86. http://www.sign.ac.uk/pdf/sign86.pdf





- Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006; (1): CD003476.
- Banerjee S. The use of antipsychotic medication for people with dementia: time for action. A Report for the Minister of State for Care Services by Professor Sube Banerjee. London: Stationary Office, 2009
- National Dementia and anti-psychotic prescribing audit 2012. www.ic.nhs.uk/dementiaaudit
- Polypharmacy Guidance 2015, NHS Scotland <u>http://www.sign.ac.uk/pdf/polypharmacy_guidance.pdf</u>

References

- Veterans' Medicines Advice and Therapeutics Education Services; Topic 39 Thinking clearly about anti-cholinergic burden 2014
- Kirsty TM Rodger et al, Expert opinion on the management of pain in hospitalised older patients with cognitive impairment: mixed method analysis of a national survey. BMC Geriatr. 2015; 15:56
- Sivaraaman K, Vajiala VS, Seizures in setting of dementia. Curr Treat Options Neurol. 2015 Apr:17(4):342